(Received 16 April 1963)
The radio-immunoelectrophoretic technique for the assay of insulin in human sera developed by Yalow & Berson (1960) has been applied to glucagon (Unger et al. 1959) and to growth hormone (Hunter & Greenwood, 1962b) . The ability of 131I-labelled hormones to compete with unlabelled hormones for antibody to the unlabelled hormone has also been utilized in assays based on the precipitation of antigen-antibody complex for glucagon (Grodsky, Hayashida, Peng & Geschwind, 1961) and for human growth hormone (Utiger, Parker & Daughaday, 1962) . Immunoelectrophoretic procedures require the routine preparation of small amounts of 13I-labelled hormones of very high specific radioactivity. The method used successfully for insulin by Yalow & Berson (1960) (McFarlane, 1958) for the labelling of insulin but no experimental details are available. Human growth hormone has been iodinated by Utiger et at. (1962) by using modifications of the method of Yalow & Berson (1960) and Staub, Springs & Elrick (1957) . They report specific radioactivities of up to 5 tc/clg., with 0-25-2-0 atoms of total iodine/molecule, by using 10-20 mc of carrier-free sodium [13I] iodide and 0 2-1 0mg. of human growth hormone. This level of specific radioactivity, though adequate for methods based on precipitation, is inadequate for the immunoelectrophoretic technique.
The following method has been developed to allow the rapid preparation of 1F5-2-5 tg. of l3lJ-labelled human growth hormone with specific radioactivities of 250-590 pc/pg. (60-75 % efficiency) by using 2-4 mc of carrier-free sodium [131I]iodide and 5,ug. of human growth hormone. Chloramine-T is used as the oxidizing agent. The 31I-labelled hormone is calculated to contain up to 1*2 atoms of iodine/molecule. In these preparations there are no discrete immunologically inactive components. With specific radioactivities of up to 300 ,c/pg. the preparations are quantitatively identical with the unlabelled hormone as measured by an immunoelectrophoretic method (Hunter & Greenwood, 1962 b) . At 500 and 750 ,uc/lg. there is a progressive loss of affinity for the rabbit anti-(human growth hormone) serum.
A preliminary report of the method has been published (Hunter & Greenwood, 1962 a) .
MATERIALS
Buffer8. All buffers were sodium salts. Human growth hormone. Human growth hormone (Raben, 1959 ) is referred to as growth hormone. Solutions for iodination were made by adding growth hormone (5 mg.) 131I-LABELLED HUMAN GROWTH HORMONE to water (1 ml.), with stirring of the suspension, followed by the addition of 1N-NaOH (0-1 ml.). The clear solution was diluted to 200 ,ug./ml. with 0 05M-phosphate buffer, pH 7 5, and samples were stored at -200 for up to 2 months. Initially a gift of human growth hormone from the Clinical Endocrinology Committee of the Medical Research Council was used. Batches of growth hormone were then prepared by the method of Raben (1959) by using acetone-dried pituitaries. These were kindly collected by Dr J. Clark, New Sussex Hospital, Brighton. Both of these preparations were subsequently shown to contain an immunologically inert component which was removed by gel-filtration on Sephadex G-200 The radioactivity is counted by using a Panax scintillation counter (USC-B) with a well-type sodium iodide crystal with the geometry modified such that 2 mc in 0-05 ml. gives approx. 400 counts/see. The lid of the lead castle is removed and the sample, in a 1 in. lead pot, placed 30 cm. above the aperture. The rubber cap is removed after the preparation is completed, and counted separately, with the same geometry.
To the sample is added 0-025 ml. of 0-5M-phosphate buffer, pH 7-5. Immediately thereafter growth hormone (5,ug.) followed by fresh chloramine-T (100,ug.), each in 0-025 ml. of 0 05M-phosphate buffer, pH 7.5, are added.
After each addition, made by injection through the rubber cap with an Agla micrometer syringe. the contents of the vial are briefly mixed. Immediately after mixing the chloramine-T, sodium metabisulphite is added [0-1 ml. of a solution (2-4 mg./ml.) in 0-05M-phosphate buffer, pH Separation of 131I-labelled growth hormone from the reaction mixture is carried out by gel-filtration with a column (10 cm. x 1 cm.; 1 g.) of Sephadex G-50 (Fig. 1) . Equilibration of the gel and elution from it is carried out with 0 07M-barbitone buffer, pH 8X6. Before the Sephadex column is used crystalline bovine plasma albumin (20 mg. in 1 ml. of pH 8-6 buffer) is passed through it, followed by a 20 ml. wash with the same buffer. This 'presaturation' of the Sephadex with albumin allows a subsequent recovery of 70 % of 3-4 pg. of ""L1-labelled hormone from the Sephadex.
The elution pattern, determined by counting 1 ml. eluates, is reproducible and allows for a routine collection of a non-radioactive discard fraction (1-5 ml.), a protein peak (4 0 ml.) and a salt peak (three 5 ml. fractions) into calibrated counting vials. The protein peak is collected into a vial containing bovine plasma albumin [1-0 ml. of a solution (50 mg./ml.) in 0-07m-barbitone buffer, pH 8-6]. After the counting of each fraction the amount of 1311-labelled hormone eluted is calculated and a sample diluted as required for the assay with 0 07M-barbitone buffer, pH 8-6, containing bovine plasma albumin (05 mg./ml. Pedersen, 1961) . Since the isotope abundance of ls'I in IBS-3 is not less than 90 %, the 131I-labelled hormone is then calculated to contain 0-53-0-59 atom of total iodine/molecule.
The calculations of specific radioactivity etc. assume that the specific radioactivities of the 131I-labelled growth hormone adsorbed to the reaction vial and to the Sephadex are the same as that eluted from the column. It has not been possible to verify this assumption experimentally.
The slight trailing of protein into the salt peak of a Sephadex column (Fig. 2) was determined experimentally by using unlabelled hormone (4 pg.) together with a trace of salt-free 131I-labelled growth hormone. It was then possible to calculate that the observed trailing at this level could be corrected for by increasing the calculated percentage efficiencies of transfer of 131I and specific radioactivities, as shown above, by 5 %. It was considered that a correction factor of this order could be disregarded. Lowry, Rosebrough, Farr & Randall (1951) . These showed that, of the unlabelled growth hormone adsorbed by the preliminary treatment, some 10lg. was subsequently eluted from the Sephadex with the 131I-labelled hormone. This rendered estimates of specific radioactivity based on the recovery of radioactivity invalid.
RESULTS

Adsorption of radioactivity
Addition of diluent protein after iodination.
Previous experiences with isotopically labelled human serum albumin suggested that the capacity of Sephadex to bind protein was non-specific. Crystalline bovine plasma albumin (2-5 mg.) was added after sodium metabisulphite in an attempt to decrease the amount of 131I-labelled growth hormone adsorbed. The recovery of 4,g. of 1311-labelled hormone was increased by this method to 66 % as calculated from radioactivity measurements.
A control experiment without added growth hormone gave an unexpected 5 % of the radioactivity in the protein peak, suggesting some iodination of the albumin despite the addition of sodium metabisulphite. 1311-labelled growth hormone was prepared and bovine plasma albumin added after sodium metabisulphite. The protein peak obtained by subsequent gel-filtration was subjected to electrophoresis in horse serum on cellulose acetate (Kohn, 1958) in 0-035M-barbitone buffer, pH 8-6. A trail of radioactivity was obtained from the albumin region to a peak of radioactivity in the growth hormone region, and in a single experiment a small but significant peak of radioactivity was found associated with albumin. The results suggested that the bovine plasma albumin added as carrier after sodium metabisulphite, although unlabelled, had an adsorptive capacity for sodium [131I] iodide. The recovery of unchanged sodium [131I]iodide from the reaction vial and the column was 94 % (see above). The radioactivity remaining in the vial in the routine preparation of 131I-labelled growth hormone was assumed for the purposes of calculation to be a mixture of free [1311] iodide and proteinbound 131I. However, the percentage left in the vial increased in direct proportion to the calculated specific radioactivity, suggesting a specific adsorption of the 13I-labelled growth hormone to the glass vial. This was confirmed experimentally in a series of six experiments by adding unlabelled growth hormone (5 ,ug. in 0-025 ml.) together with a trace of 1311-labelled growth hormone to a reaction vial containing 0-375 ml. of 0-05M-phosphate buffer, pH 7-5. After mixing, the contents of the vial were discarded and the vial was washed with 0-4 ml. of potassium iodide solution (10 mg./ml.). The radioactivity still retained in the vial was equivalent to 23 % of the initial, and two further washes only decreased this to 22 and 21 % respectively. The insertion of a single wash of the vial and pipette with 0-4 ml. of potassium iodide solution (10 mg./ml.) in control experiments without added protein gave a 94 % recovery of the sodium [131I]iodide in the salt peak. This suggested that any 1311 retained in a vial after such a wash was bound to protein. Adsorption of the eluted protein to the collection vial was elimninated by eluting into 1-0 ml. of a solution of bovine serum albumin (50 mg./ml.) in 0-07M-barbitone buffer, pH 8-6.
Optimum conditions for iodination Concentration of reactants. It was early decided to limit the amount of radioactivity handled to 2-4 mc as acceptable levels for routine laboratory work. The absolute loss of some 1-3 3g. of 131I-labelled hormone in the reaction vial precluded the lowering of the amount of growth hormone used to below 2-5 pg. Maximum specific radioactivities were obtained with 5/,g. of growth hormone. A decrease in the amount of the protein resulted in a decreased yield with essentially the same specific radioactivities, and the amount of hormone was fixed at 5 ,ug.
A preliminary series of trace-labelling experiments was carried out by allowing 10 jtg. of growth hormone to react with 0-04,ug. of [1271] iodide together with a negligible amount of [131I]iodide.
The reaction volume was varied in six steps from 0-03 to 1-5 ml. As would be expected the percentage of 127I transferred to protein by the reaction decreased from 89 to 4 % with the decrease in concentration of the reactants.
The preparations of high radioactivity were not investigated systematically but showed the expected increase in percentage transfer of 131I with decreasing volume. amount of chloramine-T was determined empirically. With chloramine-T (5,g.) no iodination took place, but transfer of 131I with up to 76 % efficiency was obtained with amounts ranging from 35 to 450 ,g. In the routine preparations 100 ,g. of chloramine-T was chosen. Exposure of human growth hormone to an oxidizing agent might be expected to cause some damage to the hormone. The degree of immunological integrity of the final product of the reaction is dependent on the specific radioactivity, as shown below. Judged immunologically, the short exposure to chloramine-T does not modify the hormone.
Iodate content of the i8otope 8ample. The radioactivity of the IBS-3 sample is derived solely from its 1311 content, but no specifications were available from The Radiochemical Centre at the time this work was carried out for the chemical form of this iodine. The sample is mainly sodium [131I]-iodide but various amounts of sodium [1311] iodate may be present. The latter is not made available for iodination by using chloramine-T and this may limit the specific radioactivity obtained. The present material has a specification of 95 % of sodium [1311] iodide.
That the iodate content is not the only variable limiting factor is shown by the results in Result8 obtained with the method Table 3 shows that in a series of 50 experiments there is a significance difference in the percentages of the radioactivity utilized when 2 and 4 mc samples of IBS-3 were used (t = 2-91; P < 0 01, 48 degrees of freedom). With one 4 mc batch of IBS-3. no iodinated protein was obtained but degraded material was eluted with unchanged nonprotein-bound 131I on the column and in a trail thereafter.
Prior treatment of several 4 mc samples of IBS-3 by heating did not produce a consistent improvement in yield. In some cases failure was thought to be caused by excessive alkalinity of the IBS-3 solution (pH > 10). It was not practical to measure the pH of the IBS-3 sample. The buffering capacity of the reaction mixture was therefore increased by the addition of 0-025 ml. of 0*5M-phosphate buffer, pH 7 5, before the addition of growth hormone and chloramine-T. (7) Vol. 89
The effect of chemically altering the growth hormone by the substitution of iodine has been investigated by preparing [127I]iodinated growth hormone containing 0-94, 9-5 and 19-3 atoms of 127I/molecule of growth hormone (mol.wt. 29000; Squire & Pedersen, 1961) . These were obtained by the routine method by using 100 jg. of growth hormone and various amounts of potassium iodide (Fig. 3) together with a negligible amount of sodium [131I]iodide, and were assayed by an immunoelectrophoretic assay (Hunter & Greenwood, 1962b) . The assay procedure is based on the ability of unlabelled growth hormone to compete with a fixed amount of 131I-labelled growth hormone for the binding sites on the limited and fixed amount of antibody present in the system. This is reflected in a decrease in the percentage of the radioactivity bound to y-globulin which is then linearly related to the logarithm of the concentration of unlabelled growth hormone. By using this parameter, [127I]iodinated growth hormone is indistinguishable from unlabelled growth hormone when up to 9-5 atoms of 127I are substituted/molecule of growth hormone (Fig. 4) sents an almost quantitative iodination of the 10 tyrosine residues/molecule of growth hormone present in our sample of growth hormone prepared by the method of Raben (1959) (Dr J. E. Eastoe, Royal College of Surgeons, unpublished work). At this level there is a marked loss of affinity for the antiserum. The residual immunological activity is not due to a small percentage of unlabelled growth hormone in the preparation, since a further experiment showed that it competes over the whole range (70-20 % binding) but with a different slope from that given by the unlabelled growth hormone (Fig. 5) .
The degree of chemical substitution achieved in the preparation of '3l1-labelled growth hormone is well below the 9-5 atoms/molecule shown above to cause no immunological damage. The highest specific radioactivity obtained (750 uc/,ug.) is calculated to contain 1-50 atoms of total iodine/ molecule of growth hormone. The electrophoretic pattern of this material on starch-block electrophoresis (Kunkel & Slater, 1952) shows a slight broadening of the peak and a slight increase in mobility towards the anode. This might be expected from the conversion of tyrosine residues into iodinated tyrosine residues.
We have no evidence for radiation damage to growth hormone by the method: no discrete degradation products as noted by Utiger et al. V31I-LABELLED HUMAN GROWTH HORMONE (1962) have been observed. In excess of antiserum 96% of the "l5I-labelled hormone is capable of reacting with the immune y-globulin of the antiserum to the unlabelled hormone. This suggests that under our conditions growth hormone does not receive a damaging level of radiation. These conditions include the high yield of the reaction, the rapid removal of the unchanged ['111] iodide and the dilution of the ""1I-labelled hormone with albumin within 20 min. of its preparation.
The chemical reagents used in the method (chloramine-T, sodium metabisulphite and potassium iodide) do not alter the immunological integrity of growth hormone. This is shown by the identical behaviour of unlabelled growth hormone and growth hormone labelled with up to 9 5 atoms of 271I/molecule with the use of these reagents.
We have evidence that the radiochemical reagent used can cause a subtle change in the immunological reactivity of the growth hormone which is not readily determined. The variable yields (Table 3 ) and variable affinities (Fig. 6 ) obtained by using growth hormone of higher specific radioactivity (400-600 ,uc/,ug.) do not allow the routine use of these preparations. The variation appears due to unknown factors in the 4 mc samples of carrier-free [131I]iodide and was not investigated further.
DISCUSSION
There are many methods available for the labelling of proteins with "3"I (cf. Taurog & Chaikoff, 1957) , and several of these have been applied to hormonally active proteins (Yalow & Berson, 1960; Unger et al. 1959; Grodsky et al. 1961; Utiger et al. 1962; Samols & Williams, 1961 have successfully applied the present method to the preparation of '31I-labelled insulin and other proteins.
In the present method no discrete degradation products have been noted on electrophoresis and, judged by one immunological parameter, growth hormone of high specific radioactivity (up to 700 ,c/pg.) was identical with the unlabelled hormone. However, the highest radioactivities obtained by using 4-6 mc gave variable yields due to unknown factors in the samples of [131I]iodide, and by the most sensitive immunological parameter were shown to have a decreased affinity for the antiserum.
With the lower amount of [131I]iodide (2 mc), yielding specific radioactivities of 200-300 zcl/tg., the 1311-labelled hormone was indistinguishable from the unlabelled hormone.
The distribution of radioactivity in an experiment, together with the behaviour of protein and iodide on the glass vial and the Sephadex column, allows the specific radioactivity and the amount of hormone recovered to be calculated. It is assumed that none of the [131I] iodide is utilized for nonspecific oxidation (cf. Hughes & Straessle, 1950) . The theoretical yields of [271I]iodinated growth hormone obtained by using calculated amounts of [127I] iodide is evidence that, under the conditions of the method, namely an excess of oxidizing agent and a step involving sodium metabisulphite, all of the iodine utilized is combined with tyrosine residues.
The rapid separation of protein and salt achieved by gel-filtration is well known, and its application to the method has obvious advantages. The absorptive capacity for protein was shown to be low (approx. 15 5. The loss of immunological reactivity at high specific radioactivities or at high levels of chemical substitution with [127I] iodine is demonstrated.
